Immunocore Holdings plc (IMCR)
| Market Cap | 1.42B +3.7% |
| Revenue (ttm) | 400.02M +29.0% |
| Net Income | -35.51M |
| EPS | -0.71 |
| Shares Out | 50.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 488,611 |
| Open | 28.12 |
| Previous Close | 27.92 |
| Day's Range | 27.70 - 28.82 |
| 52-Week Range | 27.44 - 40.72 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 66.33 (+137.66%) |
| Earnings Date | May 7, 2026 |
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ... [Read more]
Financial Performance
In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price target is $66.33, which is an increase of 137.66% from the latest price.
News
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore Holdings Transcript: 25th Annual Needham Virtual Healthcare Conference
The platform enables broad targeting of cancer and immune diseases, with KIMMTRAK driving strong revenue and global growth. Key upcoming milestones include pivotal data readouts in melanoma, HIV, and autoimmune programs, supported by a robust cash position and strategic flexibility.
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn.
Immunocore Holdings Transcript: Leerink Global Healthcare Conference 2026
KIMMTRAK continues to drive strong commercial growth and is expanding into new indications, with pivotal data readouts expected in cutaneous melanoma, lung, and ovarian cancer in 2024. The pipeline also advances in HIV and autoimmune diseases, supported by a robust cash position and strategic investments.
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore Holdings Earnings Call Transcript: Q4 2025
KIMMTRAK delivered $400M in 2025 net sales (29% YoY growth), with strong global adoption and a robust pipeline spanning oncology, infectious disease, and autoimmune. Three phase III trials are ongoing, and key data readouts are expected in 2026, supported by $864M in cash.
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore announces R&D leadership evolution
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice ...
Immunocore Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted strong commercial growth for KIMMTRAK, with significant expansion plans in melanoma and new tumor types. Multiple phase III trials and pipeline assets, including PRAME and PIWIL1, are advancing, with major data readouts expected from 2026 onward.
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US communit...
Immunocore Holdings Transcript: Jefferies London Healthcare Conference 2025
The conference highlighted strong commercial growth for KIMMTRAK, robust pipeline progress in oncology, infectious disease, and autoimmune programs, and a solid financial position with $892 million in cash. Key upcoming milestones include multiple Phase 3 trial readouts and new clinical data across indications.
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA...
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM...
Immunocore Holdings Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
AI and global partnerships drive innovation and efficiency, while KIMMTRAK's market penetration nears maturity with ongoing expansion. Multiple phase 3 trials and a robust pipeline in oncology, autoimmune, and infectious diseases are supported by strong financials and disciplined spending.
Immunocore Holdings Transcript: Cantor Global Healthcare Conference 2025
The company is advancing multiple late-stage trials, with KIMMTRAK showing strong commercial performance and extended patent protection. Key data readouts in 2026, especially for TEBE-AM and PRAME, are expected to drive significant value, while pipeline programs in oncology and infectious diseases progress toward pivotal milestones.
Immunocore Holdings Earnings Call Transcript: Q2 2025
KIMMTRAK delivered strong H1 2025 results with $192M in revenue, 32% growth year-over-year, and robust U.S. and European performance. Three Phase III trials are progressing, with continued pipeline expansion and a strong cash position supporting future growth.
Immunocore reports second quarter financial results and provides a business update
KIMMTRAK ® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel ther...
Immunocore Holdings Transcript: Jefferies Global Healthcare Conference 2025
KIMMTRAK continues robust growth with strong US and international penetration, extended therapy duration, and a leading survival benefit. Multiple pivotal trials in melanoma and new pipeline programs, including PRAME and PWIL, are advancing, with key data readouts expected over the next two years.
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Pha...
Immunocore Holdings Transcript: 24th Annual Needham Virtual Healthcare Conference
The session highlighted robust commercial growth, innovative TCR-based therapies, and a diverse pipeline spanning oncology, infectious disease, and autoimmune indications. Key clinical milestones are expected in the next 12–18 months, with strategic focus on data-driven development and potential partnerships.